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have no GVHD. The remaining patient has not relapsed but has
chronic GVHD of the liver and GI tract. Despite the high rate
of relapse seen in this series all patients are currently in molec-
ular remission with a performance status of 100% and without
extensive CGVHD. Thus Bu/Cy appears to be an effective
approach and avoids TBI-speciﬁc toxicity.However frequent
monitoring of disease status is essential to ensure that relapse is
ascertained in a timely manner and appropriate interventions
are taken.
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Metachromatic leukodystrophy is an autosomal recessive lysoso-
mal storage disorder caused by arylsulfatase A deﬁciency (ARSA).
ARSA prevents the breakdown of cerebroside 3-sulfatate. Sulfati-
des accumulate within lysosomes of myelin forming cells in the
central and peripheral nervous system causing demyelination and
progressive neurologic deterioration that leads to dementia, sei-
zures, blindness, deafness and subsequent death. It has a wide
variability in age of onset and disease severity. We hypothesized
that transplantation of umbilical-cord blood from unrelated donors
would positively alter clinical outcomes in patients affected with
MLD who are minimally symptomatic.
Fourteen patients with Metachromatic Leukodystrophy referred
to Duke University Medical Center, underwent transplantation
with umbilical cord blood from unrelated donors after myeloabla-
tive chemotherapy. Age at transplant ranged from 0.17 to 16.4
years with a median of 5.2 years. Engraftment, survival, neuro-
physiologic measures, and neurodevelopmental function were se-
rially evaluated.
Thirteen of 14 patients engrafted after initial transplant. One
patient underwent a second transplant, with successful engraft-
ment. Eight patients are surviving, 4 died of viral infections, 1 of
respiratory failure and one of EBV lymphoma. BAERS and NCV
became abnormal early in the disease course and continued to
worsen after transplant. EEG and VEP were only abnormal later in
the disease course.
Transplantation of umbilical-cord blood from unrelated donors
was beneﬁcial to asymptomatic children. Mildly symptomatic chil-
dren showed deterioration of motor skills, but maintained cogni-
tive function at pre transplant level. Children with moderate to
severe disease at the time of transplant showed no improvements in
neurodevelopmental function. As in other leukodystrophies, early
intervention is necessary for optimal outcome.
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MPS II or Hunter’s Syndrome is due to the deﬁciency of the
lysosomal enzyme iduronate sulfatase that results in lysosomal
accumulation of dermatan and heparan sulfate, with progressive
tissue and organ dysfunction, and in the severe form, premature
death. The severe form of MPS II is characterized by mental
retardation, communicating hydrocephalus, hearing impair-
ment, coarse facial features, hepatomegaly, obstructive airway
disease, cardiac dysfunction, joint stiffness and skeletal involve-
ment. They typically die in their mid teens secondary to severe
neurological involvement and/or airway obstruction compli-
cated by cardiac disease. Bone marrow transplantation, tested
more than a decade ago, in a few patients was not felt to be
beneﬁcial. We hypothesized that unrelated umbilical cord blood
transplantation would be beneﬁcial if treatment is offered before
patients have severe CNS disease. Between December 02 and
October 2005, 5 patients with MPS II received unrelated um-
bilical cord blood transplantation at Duke University Medical
Center. The patient’s age at transplant ranged from 0.26 to 3.4
years with a median of 1.4 years. Follow up ranged from 1.7 to
3.7 years with a median of 1.9 years. Four patients engrafted full
donnor and one had mixed donnor chimera. This patient died of
GvHD complications after a second transplant. The 4 survivors
have limitted skin GvHD. The oldest patient required a VP
Shunt because of increased intracraneal pressure. He had sinus-
itis and developed a subdural empyema that required surgical
drainage. All patients have mild hearing loss. The four surviving
patients continue to gain cognitive, language, adaptive and mo-
tor skills with the oldest patient having slower gains.
We conclude that patients with MPS II succesfully treated with
unrelated umbilical cord blood transplantation continue to gain
neurodevelopmental skills in all areas despite mild hearing loss.
Further follow up will be needed to determine if the adequate rate
of skill acquisition will continue.
170
VENO-OCCLUSIVE DISEASE IN PEDIATRIC HSCT: THE CHILDREN’S ON-
COLOGY GROUP EXPERIENCE
Nieder, M.L.1, Hale, G.A.2, Wall, D.A.3 1All Children’s Hospital, St.
Petersburg, FL; 2St. Jude Children’s Research Hospital, Memphis, TN;
3Texas Transplant Institute, San Antonio, TX.
Veno-occlusive disease (VOD) of the liver occurs in a minority
of children undergoing HSCT. Historically, the incidence and
severity of this transplant-related complication is lower in the
pediatric population than in their adult counterparts undergoing
myeloablative transplants. Reducing the intensity of the prepar-
ative regimen is associated with less VOD, but this transplant
approach is not commonly used in the pediatric setting. To
determine the incidence and severity of VOD in children, we
surveyed each of the approved transplant centers in the Chil-
dren’s Oncology Group. We received surveys from 38 centers
(45% response). From January 1, 2003 through December 31,
2005, these COG centers performed 2,725 transplants (45% of
COG total). These centers performed an average of 24 trans-
plants per year (range 8-188). Table 1 summarizes our ﬁndings.
The overall incidence of VOD was 10.3% (mild3.1%;
mod5.2%; severe 2%). Of the children with VOD, 18.5%
received Deﬁbrotide (DF) (usually on compassionate basis).
There were 49 children who died from VOD, representing a
mortality rate of 1.8% for the total cohort but 17% for those
who develop signs of VOD. These ﬁndings suggest that VOD is
still a notable complication in the pediatric HSCT setting, with
7.2% of patients overall developing moderate or severe disease.
Since a majority (93%) of pediatric HSCT are myeloablative,
VOD is expected to remain a major cause of transplant related
morbidity and mortality. Thus, it is important to study new
agents and strategies that can reduced this complication in
children.
COG Transplants 2003-2005*
2003 2004 2005 Total
# of Allo 504 510 513 1,527
# of Auto 415 343 440 1,198
# of RIC 73 58 69 200
Unrelated 260 268 259 787
VOD-mild 32 32 20 84
VOD-mod 36 48 57 141
VOD-severe 18 17 21 56
VOD-Death 7 16 26 49
Total VOD 86 97 98 281
*45% of COG Transplant Centers reporting
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